Pharmaceutical - UK, Regulation

Filter

Current filters:

UKRegulation

Popular Filters

1 to 25 of 128 results

NICE recommends Sovaldi and Olysio for hepatitis C

NICE recommends Sovaldi and Olysio for hepatitis C

25-02-2015

The UK’s National Institute for Health and Care Excellence (NICE) has published final guidance recommending…

Anti-viralsGilead SciencesJanssenOlysioPharmaceuticalRegulationSovaldiUK

NICE recommends AbbVie's Humira and Merck's Remicade and Simponi for ulcerative colitis

NICE recommends AbbVie's Humira and Merck's Remicade and Simponi for ulcerative colitis

25-02-2015

The UK’s health regulator, the National Institute for Health and Care Excellence (NICE) has recommended…

AbbVieGastro-intestinalsHumiraMerck & CoPharmaceuticalRegulationRemicadeSimponi InjectionUK

NICE recommends Pfizer's Inlyta but not Dendreon's Provenge

NICE recommends Pfizer's Inlyta but not Dendreon's Provenge

25-02-2015

The UK’s National Institute for Health and Care Excellence has recommended Inlyta (axitinib), marketed…

DendreonInlytaOncologyPfizerPharmaceuticalPricingProvengeRegulationUKValeant Pharmaceuticals International

NICE makes preliminary recommendation on Allergan's Ozurdex for macular edema

NICE makes preliminary recommendation on Allergan's Ozurdex for macular edema

20-02-2015

The UK’s National Institutes of Health and Care Excellence has recommended Ozurdex (dexamethasone),…

AllerganDexamethasoneOphthalmicsOzurdexPharmaceuticalRegulationUK

NICE gives green light to Bayer’s Eylea for DME

20-02-2015

In a preliminary recommendation issued today, England’s health costs watchdog the National Institute…

BayerEyleaOphthalmicsPharmaceuticalPricingRegulationUK

NICE final draft guidance recommends Norgine's Targaxan

NICE final draft guidance recommends Norgine's Targaxan

19-02-2015

The UK’s National Institute for Health and Care Excellence has published its final draft guidance recommending…

Nephrology and HepatologyNeurologicalNorginePharmaceuticalRegulationTargaxanUK

Pharma violates own marketing regulations, Swedish study alleges

Pharma violates own marketing regulations, Swedish study alleges

19-02-2015

A new report from Lund University in Sweden claims to show how the pharmaceutical industry, time and…

Markets & MarketingPharmaceuticalRegulationSwedenUK

Janssen disappointed at SMC decision on Zytiga

09-02-2015

Janssen, a UK-based subsidiary of US health care giant Johnson & Johnson is disappointed with the Scottish…

JanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationUKZytiga

UK’s NICE backs Bayer’s Xarelto for reducing risk of secondary events in ACS

UK’s NICE backs Bayer’s Xarelto for reducing risk of secondary events in ACS

23-01-2015

The National Institute for Health and Care Excellence (NICE), the health costs watchdog for England,…

BayerCardio-vascularPharmaceuticalPricingRegulationUKXarelto

NICE set to recommend Boehringer’s type 2 diabetes drug Jardiance

NICE set to recommend Boehringer’s type 2 diabetes drug Jardiance

22-01-2015

England’s health care costs watchdog the National Institute for Health and Care Excellence (NICE) has…

Boehringer IngelheimDiabetesJardiancePharmaceuticalPricingRegulationUK

Novo Nordisk's Victoza granted label extension in the UK

Novo Nordisk's Victoza granted label extension in the UK

20-01-2015

A license extension has been granted in the UK for Victoza (liraglutide) from Danish insulin giant Novo…

Nephrology and HepatologyNovo NordiskPharmaceuticalRegulationUKVictoza

Shield Therapeutics' MAA for Ferracru accepted for review by EMA

Shield Therapeutics' MAA for Ferracru accepted for review by EMA

07-01-2015

Independent UK pharma company Shield Therapeutics has received acceptance for review of the Marketing…

FerracruHematologyPharmaceuticalRegulationShield TherapeuticsUK

UK’s NICE says cost of Celgene’s Abraxane is not justified by its limited benefit

UK’s NICE says cost of Celgene’s Abraxane is not justified by its limited benefit

30-12-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has today published…

AbraxaneCelgene CorpOncologyPharmaceuticalRegulationUK

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

17-12-2014

In final guidance published today, UK health cost watchdog the National Institute for Health and Care…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

UK’s NICE recommends Pfizer’s Inlyta for kidney cancer

UK’s NICE recommends Pfizer’s Inlyta for kidney cancer

16-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued new…

InlytaOncologyPfizerPharmaceuticalPricingRegulationUK

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

15-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) have recommended…

BayerOncologyPharmaceuticalPricingRegulationUKXofigo

NICE says ‘yes’ to Remicade, Humira and Simponi for ulcerative colitis

NICE says ‘yes’ to Remicade, Humira and Simponi for ulcerative colitis

12-12-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has issued…

AbbVieGastro-intestinalsHumiraMerck & CoPharmaceuticalPricingRegulationRemicadeSimponi InjectionUK

UK industry makes third quarter PPRS payment, Department of Health sets 2015 percentage at 10.36%

UK industry makes third quarter PPRS payment, Department of Health sets 2015 percentage at 10.36%

11-12-2014

The UK pharma industry has made its third quarter payment to underwrite the growth of the medicines bill…

ABPIDepartment of HealthPharmaceuticalRegulationUK

FDA accepts NDA filing from AstraZeneca for Iressa

FDA accepts NDA filing from AstraZeneca for Iressa

02-12-2014

The US Food and Drug Administration has accepted for filing the New Drug Application from Iressa (gefitinib)…

AstraZenecaIressaOncologyPharmaceuticalRegulationUK

NICE reverses October decision and approves Roche's Gazyvaro

NICE reverses October decision and approves Roche's Gazyvaro

02-12-2014

The UK’s National Institute for Health and Care Excellence (NICE) has reversed its decision on Gazyvaro…

GazyvaroOncologyPharmaceuticalRegulationRocheUK

UK uses fewer branded medicines per person than comparable countries and is still using older therapies

UK uses fewer branded medicines per person than comparable countries and is still using older therapies

27-11-2014

The Association of the British Pharmaceutical Industry has published new research showing that UK use…

ABPIMarkets & MarketingPharmaceuticalRegulationUK

NICE updated guidance backs Novartis’ Glivec for GIST

26-11-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued final…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

UK's NICE recommends Selincro to help reduce alcohol dependence

UK's NICE recommends Selincro to help reduce alcohol dependence

26-11-2014

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Selincro (nalmefene)…

LundbeckNeurologicalPharmaceuticalRegulationSelincroUK

AstraZeneca’s Duaklir Genuair approved in the EU for COPD

AstraZeneca’s Duaklir Genuair approved in the EU for COPD

25-11-2014

The European Commission has granted marketing authorization for Anglo-Swedish pharma major AstraZeneca’s…

AstraZenecaDuaklir GenuairPharmaceuticalRegulationRespiratory and PulmonaryUK

1 to 25 of 128 results

COMPANY SPOTLIGHT

Menarini

Back to top